Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

Article Abstract:

A new T-cell hepatitis C virus (HCV) genetic vaccine for protecting chimpanzees from acute hepatitis induced by challenge with heterologous virus is discussed. Massive expansion of peripheral and intrahepatic HCV-specific CD8+ T lymphocytes that cross-reacted with vaccine and virus epitopes caused the suppression of acute viremia in vaccinated chimpanzees.

Author: Folgori, Antonella, Capone, Stefania, Ruggeri, Lionello, Meola, Annalisa, Sporeno, Elisabetta, Ercole, Bruno Bruni, Pezzanera, Monica, Tafi, Rosalba, Arcuri, Mirko, Fattori, Elena, Lahm, Armin, Luzzago, Alesandra, Vitelli, Alessandra, Colloca, Stefano, Cortese, Riccardo, Nicosia, Alfredo
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2006
Care and treatment, Complications and side effects, Diseases, Control, Dosage and administration, Chimpanzees, Viral vaccines, Hepatitis C virus

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The process development challenge for a new vaccine

Article Abstract:

Regulatory, technical and manufacturing hurdles in translating a vaccine candidate to clinic are the major challenges of vaccines development. Process development is central to successful commercialization and also is a technological foundation that underlies the manufacture of new vaccines.

Author: Buckland, Barry C.
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2005
Production management, Manufacturing processes, Product Development, Market Research & Product Development, Evaluation, Production processes, Time to market

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Battle over eye medicine gives drugmaker a dose of reality

Article Abstract:

The impact of the decision of the biotechnology company, Genentech to withdraw its eye medicine, Avastin on the patients, as well as the doctors is discussed.

Author: Hayden, Erika Check
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2008
Commodity & service prices, Management dynamics, Goods & services distribution, Channels of Distribution, Management, Prices and rates, Distribution, Genentech Inc., Company business management, Monoclonal antibodies, Company distribution practices, Company pricing policy, DNA, Avastin (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Biological products industry
Similar abstracts:
  • Abstracts: A COG in the sugar machine. Antisickling effects of an endogenous human alpha-like globin
  • Abstracts: The effects of intra-amniotic injection of periodontopathic lipopolysaccharides in sheep. Host response after reconstruction of abdominal wall defects with porcine dermal collagen in a rat model
  • Abstracts: MGMT gene silencing and benefit from temozolomide in glioblastoma. Blood lead concentration and delayed puberty in girls
  • Abstracts: MGMT gene silencing and benefit from temozolomide in glioblastoma. part 2 Gamma-Hydroxybutyric acids
  • Abstracts: Persistent low back pain. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.